Signos raised $20 million to expand its glucose monitoring platform beyond diabetes by targeting weight loss, the company said. The approach combines an over-the-counter Dexcom CGM with an app that converts glucose readings into personalized diet and lifestyle recommendations, positioning the platform as a consumer-facing behavioral tool. The financing underscores how companies are building on CGM device access to create actionable programs that aim to influence eating patterns and metabolic outcomes. For the broader category, it also reflects continued growth in “CGM for wellness” propositions, where differentiation increasingly depends on software and longitudinal guidance rather than sensor hardware. As CGM adoption expands outside traditional diabetes care, funding signals investor confidence in closed-loop engagement models—turning continuous glucose data into daily decisions—while also raising the bar for clinical validation of outcomes tied to these digital interventions.